Introduction
Wilms' tumor (WT) is one of the most common solid tumors of children and is thought to arise from embryonal undifferentiated renal mesenchyme. The genetic etiology of WT is heterogeneous, and several genes hypothesized to play a role in tumor development have been localized (reviewed in Huff, 1998) . The only Wilmstumor gene identified to date, WT1 on chromosome 11p13 is vital for normal genitourinary development (Call et al., 1990; Gessler et al., 1990; Kreidberg et al., 1993) . Mutations that inactivate WT1 function are observed in about 5-20% of Wilmstumors (Gessler et al., 1994; Varanasi et al., 1994; Huff, 1998) .
WT1 encodes a zinc-finger transcription factor, which contains a transactivation domain and four zinc-finger motifs. The WT1 primary transcript undergoes two alternative splicing events, giving rise to four isoforms of mRNA (Buckler et al., 1991) . Splicing out of exon 5 removes 17 amino acids from the middle of the protein, and the other alternate splicing event results in insertion ( þ KTS isoform) or omission (ÀKTS isoform) of the KTS tripeptide between the third and fourth zinc-finger domains. The presence of the KTS peptides alters the ability of WT1 to bind target DNA sequences and subsequently to regulate transcription (Madden et al., 1991; Drummond et al., 1994; Wang et al., 1995) .
One of the DNA motifs recognized by WT1 is the early growth response-1 (EGR1) binding site, GCGGGGGCG. However, whereas EGR1 binding of this site activates transcription of downstream genes, WT1 binding often results in transcriptional repression (Rauscher et al., 1990; Wang et al., 1995) . Many potential target genes that contain EGR1/WT1 binding sites in their promoters have been identified. They include the genes c-MYC, c-MYB, IGF1R, TGFB1, EGR1, RAR-a-1, TMP21, E-cadherin, N-myc, and CTGF (Madden et al., 1991; Werner et al., 1993; Dey et al., 1994; Goodyer et al., 1995; Hewitt et al., 1995; McCann et al., 1995; Englert et al., 1997; Zhang et al., 1999; Hosono et al., 2000; Stanhope-Baker and Williams, 2000) . A second potential DNA-binding motif for WT1 consists of TCC repeats, which have been identified in the promoters of PDGFA (Wang et al., 1992) and EGFR (Englert et al., 1995) . Another highaffinity WTE site (GCGTGGGAGT) has been reported to mediate binding by WT1 (-KTS) to the promoters of amphiregulin (Lee et al., 1999) and Bcl 2 (Hewitt et al., 1995) . Cotransfection assays have suggested that most of these genes are repressed by WT1. Inducible WT1 expression experiments have suggested that WT1 can activate expression of some genes, among them amphiregulin (Lee et al., 1999) . Since many of the genes putatively repressed by WT1 act to promote cell proliferation, a reasonable model for the role of WT1 in tumorigenesis is that inactivation of WT1 results in increased expression of those growth stimulatory genes.
In this study, we used cDNA microarrays to compare the expression of the above putative WT1 targets in two types of tumor samples: tumors with mutant WT1 versus those with wild-type WT1. We hypothesized that the expression of WT1 targets would differ between wild-type and WT1-mutant tumors if dysregulation of those putative targets was a critical consequence of WT1 mutations during tumorigenesis. Here we report that expression of c-MYC, one of the 14 putative WT1 target genes assessed, was significantly elevated in WT1-mutant tumors compared to the WT1-wild-type tumors. This finding suggests that c-MYC is a critical effector of WT1 mutations during tumorigenesis.
Results

Assessment of different parameters used in the study
The results of our pilot studies to establish appropriate hybridization parameters indicated that, although the sensitivity in detecting gene expression increased when 15 mg of RNA was used to prepare the probe, the relative level of gene expression did not change when differing amounts of the same RNA was used for probe preparation. Similarly, the gene expression profile was robust to using total RNA versus polyA-selected RNA (P ¼ 0.698). Treatment of RNA with DNase before probe preparation had no discernable effect on the gene expression profile (P ¼ 0.245). This was presumably because of the absence of DNA contamination in our CsCl-purified RNA preparations.
Putative target gene expression in the two genetically defined sets of tumors
Representative examples of microarray blots showing expression of three of the putative target genes (c-MYC, EGR1, and PDGFA) in a WT1-wild-type tumor and a WT1-mutant tumor are shown in Figure 1 . For the entire sample of 31 tumors smooth t-statistics were applied to determine if putative targets of WT1 transcriptional regulation were significantly differentially expressed in the two genetically defined sets of tumors. The expression data for the 14 putative WT1 targets in WT1-mutant and WT1-wild-type tumors are summarized in Table 1 . These data demonstrate that the putative WT1 target, c-MYC, was expressed significantly differently in the set of mutant tumors compared to wild-type tumors (smooth t-value of À4.30). Its mean expression was 2.33-fold higher in WT1-mutant tumors than in WT1-wild-type tumors. These data were confirmed by our assessment of c-MYC expression using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) (TaqMan Assay) in all of the tumor samples; consistent with the microarray data, c-MYC was expressed at higher levels (2.49-fold) in WT1-mutant tumors compared to WT1-wild-type tumors.
EGR1 was also expressed at higher levels in WT1-mutant tumors than in WT1-wild-type tumors (a 1.69-fold difference) with a smooth t-value of À2.76 that was close to, but did not reach, the significance level of 3. Most of the other putative WT1 targets (BLC2, c-MYB, IGF1R, TGFB, CTGF, and amphiregulin) were expressed at higher levels in WT1-mutant tumors than in WT1-wild-type tumors. Other targets (PDGFA, TMP21, EGFR, RARA, and N-myc) were expressed at higher levels in the wild-type tumors than in the mutant tumors. However, other than c-MYC, none of the putative target genes were expressed at significantly different levels between the two groups of tumors.
Discussion
Dysregulation of genes that play key roles in regulating cell proliferation and differentiation is a common end result of genetic alterations that occur in human tumors and is an important step in tumorigenesis. For example, in colorectal carcinoma, upregulation of c-MYC and cyclin D1 expression is thought to be a critical consequence of the abrogation of the wnt-signaling pathway, which occurs by mutation of one of several genes (e.g., APC, b-catenin) (He et al., 1998; Tetsu and McCormick, 1999) . Functional ablation of the transcriptional regulator WT1 is known to be a key step in the development of a subset of Wilmstumors, presumably by dysregulation of downstream target genes that are critical for control of cell proliferation or differentiation. Consistent with this notion, in transient cotransfection assays and also inducible experimental systems, WT1 has been shown to repress or activate the transcription of a number of genes (EGFR, EGR1, PDGFA, IGF1R, TGFB, RARA, TMP21, BCL2, MYB, c-MYC, CTGF, N-myc, amphiregulin, and Ecadherin), many of which act to regulate cell growth. It is not clear, however, which of these putative target genes are the genes whose dysregulation is the mechanism by which WT1 mutations lead to tumor development. Furthermore, the cellular pathway(s) that is disrupted in tumors as a result of WT1 mutations is not known. We hypothesized that at least some of the putative WT1 target genes would be differentially expressed in tumors as a function of WT1 mutational status. Identification of such differentially expressed genes would, in turn, point to important cellular pathways for normal kidney development whose abrogation is a critical step in tumorigenesis. Identification of even one of these pathways would greatly increase the understanding of the biology of Wilmstumors.
As hypothesized, differences in the expression of some putative target genes were observed between the two genetically defined sets of Wilmstumors (Table 1 ). The greatest degree of differential expression was observed for c-MYC and EGR1 with both being expressed at higher levels in WT1-mutant tumors than in WT1-wildtype tumors. These data support previous in vitro studies suggesting that WT1 represses expression of these two genes (Madden et al., 1991; Hewitt et al., 1995) . The difference between WT1-mutant and WT1-wild-type tumors for EGR1 expression approached statistical significance (smooth t-value ¼ À2.76). cMYC was clearly statistically significantly overexpressed in WT1-mutant tumors (smooth t-value ¼ À4.30).
Our finding of increased c-MYC expression concordant with WT1 mutation status is of note for several reasons. c-MYC can immortalize primary fibroblasts, and its expression is associated with cell proliferation. Increased expression of c-MYC and/or c-MYC mutation is observed in a wide variety of human cancers (reviewed in Boxer and Dang, 2001 ). In the mouse embryonic kidney, c-MYC is expressed in both early (uninduced mesenchyme and also induced and condensing mesenchyme) and later (tubule elongation) differentiation stages, and its expression is observed in mitotically active cells in these structures. No c-MYC expression is observed in terminally differentiated structures of the kidney (Mugrauer and Ekblom, 1991) , consistent with c-MYC expression being correlated with cell proliferation. Unlike c-MYC, WT1 is (Nisen et al., 1986) . Although the WT1 mutation status was not known for these tumors, 20% of all Wilmstumors carry a WT1 mutation. Therefore, it is very plausible that the two tumors that displayed an exceptionally high level of c-MYC expression by Northern analysis did carry WT1 mutations. Similarly, the low to absent c-MYC expression observed in the other tumors reported in Nisen et al. (1986) is also consistent with our data in which WT1-wild-type tumors do express c-MYC, but at a statistically significantly lower level than WT1-mutant tumors. Overexpression of c-MYC in the renal tubular epithelium of transgenic mice results in polycystic kidney disease, abnormal cellular proliferation and, in one strain, renal cell carcinoma (Trudel et al., 1991; Geick et al., 2001 ). These data demonstrate the ability of c-MYC to play a role in the development of renal malignancies. However, because the transgene was expressed in differentiated tubule epithelium, it is not clear whether upregulation of c-MYC in undifferentiated mesenchyme would also result in neoplastic transformation.
Increased c-MYC expression is thought to be an important consequence of dysregulation of the wntsignaling pathway. This is of particular relevance for this study since b-catenin mutations occur in B10-15% of WTs (Koesters et al., 1999; Maiti et al., 2000) , and a strong correlation (Po10 À13 ) exists between the presence of WT1 and b-catenin mutations such that tumors carrying b-catenin mutations almost invariably also carry WT1 mutations and half of the tumors carrying WT1 mutations also carry b-catenin mutations (Maiti et al., 2000) . The b-catenin mutations observed in Wilmstumors, like those identified in other types of cancers, ablate phosphorylation sites and are expected to result in stabilization of b-catenin protein. This, in turn, is hypothesized to result in the increased expression of genes upregulated by the b-catenin/TCF dimer. One of the proposed target genes for this transcription complex is c-MYC. Thus, the upregulation of c-MYC we observed in the WT1-mutant tumors could potentially be a result of the presence of stabilizing b-catenin mutations in half of the set of WT1 -mutant tumors. To investigate this, we stratified our sample of 15 WT1-mutant tumors based on b-catenin mutation status. Increased expression of c-MYC was observed in those eight WT1-mutant tumors that also carried b-catenin mutations when compared to the set of seven WT1-mutant tumors with wild-type b-catenin (c-MYC expression levels of 131 and 208, respectively). However, this difference was not statistically significant, indicating that the statistically significant differential expression of c-MYC in WT1-mutant versus WT1-wild-type tumors is a function of WT1 mutation status, not b-catenin mutation status. These data suggest that in Wilms tumors WT1 is a more important regulator of c-MYC expression than is b-catenin, although they do not rule out a model by which WT1 and b-catenin act additively to regulate c-MYC.
Differences in gene expression for the other WT1 putative targets were not statistically significant between WT1-mutant and WT1-wild-type tumors. For a few of the putative target genes whose expression was close to the background-corrected threshold value of 99.73 (e.g., CTGF, CRDGF, CDH1; see Table 1 ), our assay was not sufficiently sensitive to detect potential differences between the two sets of tumors. However, expression of most of the putative target genes was sufficiently above background to ensure that assay sensitivity was not responsible for our observation that these genes were not differentially expressed. Our data then suggest that, with the exception of c-MYC and possibly EGR1, most of the putative target genes reliably assayed in this study (BCL2, MYB, IGF1R, TGFB, PDGFA, TMP21, EGFR, RARA and N-myc) are not significantly regulated by WT1 in Wilmstumors. The discrepancy between these data and the data from studies originally identifying potential targets of WT1 regulation may be a function of the cell lines used for the cotransfection and WT1-induction studies and/or the expression of the WT1 protein at nonphysiologic levels in these studies. It should be noted, however, that our data from tumors do not preclude the possibility that some of the putative target genes are regulated by WT1, but in a different tissue context.
The lack of differential expression of putative WT1 target genes also does not preclude the possibility that dysregulation of one or more of these genes is important in the etiology or progression of Wilmstumors. It is possible, for example, that dysregulation of a target gene(s) is effected by mutation of another 'WT gene' in those tumors that have not sustained mutations in WT1. If this is the case, it implies a convergence of the effect of WT1 mutations and mutations of other WT genes at the level of dysregulation of a target gene(s). However, it is clear that, while mutation of WT1 and mutation of other WT genes may affect a similar 'tumorigenic' pathway, they do not affect all of the same cellular pathways. This is evidenced by the fact that individuals with a familial predisposition to Wilmstumor in the absence of WT1 mutations do not display the congenital genitourinary anomalies (in particular, male pseudoher-maphrodism) that are associated with germline WT1 mutations. These observations argue then that WT1 plays a role in dysregulating genes in pathways critical for normal sexual differentiation and that these pathways are not affected by mutation of other WT genes.
In summary, our gene expression array data demonstrate that WT1 mutations are correlated with increased c-MYC expression and strongly suggest that the biological effect of WT1 mutations in Wilmstumors is mediated, at least in part, by upregulation of c-MYC. This in turn points to a pivotal role of c-MYC and the cellular pathways it affects in the development of WT. Future investigation of the expression and mutation status of other genes in these pathways and the effect of c-MYC overexpression in embryonal kidney tissue will help to elucidate what role c-MYC, WT1, and perhaps other WT genes, play in tumorigenesis.
Materials and methods
Wilmstumors samples
Primary tumor tissue was obtained at surgery from 31 patients following informed consent. Previous WT1 mutational analysis indicated that 15 of these 31 tumors carried germline or somatic mutations in WT1 (Huff, 1998) . All mutations are predicted to inactivate WT1 function. In all, 13 of the 15 WT1-mutant tumors carried protein truncating mutations (deletions, insertions, and nonsense mutations). One tumor carried an exon 9 missense mutation, which is thought to inactivate WT1 function because of the association of exons 8 and 9 missense mutations with the Denys-Drash syndrome of male pseudohermaphrodism, early onset renal failure, and Wilmstumors. One tumor carried a mutation at the exon 8 acceptor splice. Tumors that had not sustained WT1 mutations expressed the WT1 gene; there was no evidence of transcriptional silencing of wild-type WT1 alleles, consistent with the observation that most Wilmstumors express WT1. Tumor histology was mostly triphasic (blastemal, epithelial, stromal) in both WT-wild-type and WT1-mutant tumors, although a few mutant tumors had predominantly stromal components.
Isolation of total RNA from tissues
Total cellular RNA was extracted from snap-frozen tumors using a modification of the CsCl-gradient method of Chirgwin et al. (1979) . After isolation of total RNA, the concentration was measured by absorbance at 260 nm and the samples were stored in 70% ethanol at À801C.
Hybridization of cDNA expression array
To quantify gene expression, the Atlas Human cancer 1.2 cDNA Expression Array was used (Clontech Laboratories, Inc.). Clontech blots were chosen because they require much less RNA for probe preparation than do other microarrays, an important consideration given the limited amount of primary tumor samples available. Although RNA amplification procedures have been developed, we were concerned about possible resultant subtle skewing of the RNA population. The Human Cancer 1.2 array contains 1176 human cDNA fragments, including many putative targets of WT1: EGFR, EGR1, PDGFA, IGF1R, TGFB1, RARA, TMP21, BCL2, c-MYB, c-MYC, CTGF, N-myc, amphiregulin, and E-cadherin. Each cDNA fragment present on the blot is 200-600 bp long. To minimize cross-hybridization and nonspecific hybridization, each fragment was selected to insure that it does not contain repetitive elements or a poly(A) tail, has no homology to other fragments on the array, and has minimal homology to related gene family members.
In pilot studies we assessed the effect of various factors on the quantification of gene expression. We compared the use of different amounts of RNA (5, 10, and 15 mg) for probe preparation. We also assessed the effect of using total RNA versus polyA-selected RNA, and DNase-treated RNA versus non-DNase-treated RNA. Based on the results from these preliminary experiments (Results, below), for quantitating gene expression in the 31 tumors, 15 mg of total RNA from each tumor was reverse-transcribed using a gene-specific primer mix (Clontech protocol) to synthesize 32 P-labeled cDNA probes which were then purified using column chromatography. Arrays were then hybridized overnight at 681C with the radiolabeled cDNA probe. After a high stringency wash (0.1 Â SSC, 0.5% SDS), the filters were exposed to a PhosphorImager screen at room temperature for 72 h. The screens were then scanned with a Storm 840 PhosphorImager using ImageQuant Software (Molecular Dynamics, Sunnyvale, CA, USA). Since the amount of each cDNA fragment on the array was present in excess (10 ng), binding of cDNA to the probes was linear. In the present study, only new membranes from the same lot were used.
Quantification
Scans were quantified using ArrayVision Software (Imaging Research, Inc., St Catherines, Ontario, Canada) and a global background correction. As subtle histological differences between the tumors could result in differential expression of the commonly used 'standardizing genes' (e.g., b-actin), we corrected across blots by normalizing the backgroundcorrected intensity of each spot by the median intensity of all reliable spots on that array.
Quantitative real-time PCR (TaqMan assay)
The level of c-MYC expression in all the tumors used for microarray experiments was measured by real-time PCR analysis. Total RNA (500 ng) from tumors was reverse transcribed in a 10 ml reaction mixture containing 1 Â TaqMan RT buffer, 5.5 mm MgCl 2 , 500 mm of each dNTP, 2.5 mm random hexamers, 0.4 U/ml RNase inhibitor, and 1.25 U/ml MultiScribe Reverse Transcriptase (Applied Biosystems, Foster City, CA, USA). The RT thermal cycling conditions were as follows: 251C for 10 min, 481C for 60 min, and 951C for 5 min. Real-time quantitative PCR was performed in quadruplicate using the ABI PRISM 7900 Sequence Detection system and data were averaged. Primers and TaqMan probes for c-MYC and GAPDH were purchased from Applied Biosystems (AOD-HS00153408 ml and PDAR-4326317E). Each cDNA was amplified using TaqMan Universal PCR Master Mix (ABI-4324018) according to the following PCR conditions: 951C for 10 min, followed by 40 cycles of 951C for 15 s and 601C for 1 min. The amount of fluorescent product was measured after each cycle. Each threshold cycle (C T ), which indicates the cycle at which an increase in reporter fluorescence goes slightly over the optimal value line, was determined.
Statistical analyses
We used the newly developed smooth t-test to statistically analyse our data for differences in putative target gene expression between the WT1-mutant and WT1-wild-type sets of tumors. This method is based on the observation that the s.d. of gene expression data changes systematically as a function of the mean intensity of the gene expression (Baggerly et al., 2001; Coombes et al., in press ). In the analytical smooth t-test, genes of similar mean expression are collected into groups using a moving window, and a smooth curve is fitted to the medians of the gene-by-gene estimates of s.d. This smooth estimate of s.d. is used as the denominator to compute tstatistics. Genes that are considered differentially expressed have t-values either greater than 3 or less than À3. To assess whether genes were significantly differentially expressed as a function of WT1 mutational status, the s.d. of each gene was plotted against the mean intensity of that gene observed in WT1-wild-type and in WT1-mutant tumors.
Real-time RT-PCR data was quantitated using the DDCT method in the ABI7900 SDS software (Applied Biosystems). GAPDH was used as control for input RNA. GAPDH is a reported stably expressed housekeeping gene that, we confirmed from the expression array data, was expressed equally in all the tumors. Abbreviations WT1, Wilms' tumor gene; WT, Wilms' tumor; CsCl, cesium chloride; RT-PCR, reverse transcriptase -polymerase chain reaction; APC, adenomatous polyposis coli gene; TCF, T-cell factor.
